Last reviewed · How we verify
NCT07237412: ReViseNetFeed
Neurofeedback-based Visual Restoration Therapy
NA trial testing neurofeedback in Visual Field Defect Homonymous Bilateral in 14 participants. Currently enrolling.
30 April 2028
Quick facts
| Lead sponsor | Adrian Guggisberg |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 17 November 2025 |
| Primary completion | 30 April 2028 |
| Estimated completion | 30 April 2028 |
| Sites | 2 locations across Switzerland |
Drugs / interventions tested
- neurofeedback
Conditions studied
- Visual Field Defect Homonymous Bilateral — all drugs for Visual Field Defect Homonymous Bilateral →
Sponsor
Adrian Guggisberg
Who can join
Adults 50 to 70, any sex, with Visual Field Defect Homonymous Bilateral. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Visual field defects are a common consequence of acquired brain injuries and affect people of all ages. These vision problems make everyday life more difficult-for example, when reading, driving, or moving around safely. However, there is currently no effective therapy to improve visual field defects. Previous training methods have focused on maximizing brain activity during a task. However, new findings show that the best performance is achieved when the brain is already in a state of high communication before the task. Our research shows that people can learn to increase communication between brain regions through neurofeedback. Studies have shown that neurofeedback can help people after a stroke: it improves the coordination of brain areas that are important for movement, thereby helping to increase mobility. Building on these findings, this study investigates whether EEG neurofeedback can support the visual centers in the brain to improve vision in patients with chronic visual field defects. The main objective of the study is to evaluate the effectiveness of neurofeedback in improving visual field defects. More specifically, the investigators are investigating the development of visual ability (expansion of the visual field, contrast sensitivity).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07237412
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of neurofeedback
Trials testing the same drug.
- NCT07085494 — Neurofeedback and Cognitive Training for PBTS · NA · enrolling by invitation
- NCT04902365 — Neurofeedback in Visual Snow · NA · unknown
- NCT03964545 — Neurofeedback in Adolescents With Emotion Dysregulation · NA · completed
- NCT03093142 — The Treatment Effectiveness of Combined tDCs and Neurofeedback (NF) for Patients With Cognitive Deficits After Stroke · NA · completed
- NCT03376373 — Neurotherapy to Promote Emotion Recognition in Autism · NA · completed
Other recruiting trials for Visual Field Defect Homonymous Bilateral
Currently open trials in the same condition.
- NCT05141604 — Feasibility Test of Virtual Reality Obstacle Detection for Low Vision Walking · NA · active not recruiting
Other Adrian Guggisberg trials
Trials by the same sponsor.
- NCT05570578 — Effects of Transcranial Direct Current Stimulation (tDCS) on Brain Organization and Naming in Aphasic Patients. · NA · recruiting
- NCT03342534 — Effect of tDCS on Brain Organization and Motor Recovery · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07237412 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Adrian Guggisberg
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07237412.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing